Reminder: Revance Investors Alerted to Ongoing Class Action Lawsuit

Investors in Revance Therapeutics, Inc. have been reminded by Levi & Korsinsky about the pending class action lawsuit against the company. The lead plaintiff deadline for this lawsuit is March 4, 2025. This legal action stems from allegations that Revance made misleading statements and failed to disclose important information regarding its business practices and prospects.

The lawsuit claims that Revance violated the Securities Exchange Act of 1934 by providing misleading information to investors. This misinformation allegedly caused investors to suffer losses when the truth about the company’s situation was revealed. Investors who purchased Revance securities between February 18, 2020, and November 30, 2024, may be eligible to participate in the class action lawsuit.

One of the key issues in the lawsuit is the company’s announcement that it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning its Biologics License Application (BLA) for DAXI. This letter indicated that the FDA had identified deficiencies that prevented the approval of the BLA in its current form. Revance’s stock price dropped significantly following this announcement, causing financial harm to investors.

In addition to the CRL, the lawsuit also alleges that Revance made false statements about the efficacy of DAXI and its potential for FDA approval. The company is accused of misleading investors by exaggerating the drug’s prospects and failing to disclose the risks associated with its regulatory approval process.

Investors who suffered losses as a result of their investment in Revance securities may be entitled to compensation. It is essential for affected investors to take action before the lead plaintiff deadline of March 4, 2025. By participating in the class action lawsuit, investors can seek to recover their losses and hold Revance accountable for its alleged misconduct.

Levi & Korsinsky is urging investors to contact the firm to learn more about their legal rights and options in this case. The firm is committed to advocating for the interests of investors who have been adversely affected by alleged securities fraud. Investors who believe they may have a claim in this lawsuit should not hesitate to seek legal advice and representation. The deadline for the lead plaintiff in this case is fast approaching, and affected investors should act promptly to protect their rights.